Work

Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Year: 2015

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2015.07.630

Authors: S. Kumar, R. Vij, J.L. Kaufman, J. Mikhael, T. Facon, P. Moreau, M. Amiot, S. Alzate, L. Morris, J. Ross, M. Dunbar, M. Zhu, S. Agarwal, J. Leverson, S. Enschede, R. Humerickhouse, C. Touzeau

Institutions: Mayo Clinic, Winship Cancer Institute, Mayo Clinic in Arizona, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Nantes, AbbVie (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2236090794

FWCI: 0.227

Cites:

Cited by: 1

Related to: 10